论文部分内容阅读
近日,国家干细胞工程技术研究中心主任韩忠朝团队发表在Stem Cell Research&Therapy上的一篇题为《VCAM-1+胎盘绒毛膜间充质干细胞显示出强有力促血管生成活性》的文章受到国内外相关领域的高度关注。该文章阐述了血管细胞黏附分子-1+(VCAM-1+)胎盘绒毛膜间充质干细胞(CV-MSC)具有良好的促血管生成活性,成为理论走向临床治疗的重要一步。许多研究已经证明,来自不同组织源的间充质干细胞对缺血性疾病有不同程度的治疗效果,有研究人员认为是由于间充质干细胞的旁分泌
Recently, an article entitled “VCAM-1 + placental choriocarcino mesenchymal stem cells showing potent pro-angiogenic activity” published by SONG Han-chao, director of the National Center for Stem Cell Engineering and Technology, was published in the Stem Cell Research & Therapy by other relevant fields at home and abroad Highly concerned. This article describes that VCAM-1 and placental chorionic mesenchymal stem cells (CV-MSCs) have good pro-angiogenic activity and become an important step towards clinical treatment. Many studies have shown that mesenchymal stem cells from different tissue sources have different degrees of therapeutic effect on ischemic diseases. Researchers believe that due to the secretion of mesenchymal stem cells